本研究旨在描述一种用于远端股骨巨细胞瘤（GCTB）的三维打印纵梁型假体的设计和手术技术，并评估其短期临床效果。从2018年6月至2021年1月，回顾性研究了9例患有Ⅰ或Ⅱ级远端股骨GCTB的连续病例，这些患者接受了扩大性病灶内根治术后结合自体移植重建，以评估其临床和影像学结果。所有患者在手术后进行了30.8 ± 7.5个月（18-42个月）的随访。手术前患肢骨下关节软骨下骨比例的均值为31.8% ± 9.6%（范围为18.2%～50.2%），软骨下骨厚度的均值为2.2 ± 0.8 mm（范围为1.2-4.0 mm）。最终随访时，所有患者均无局部复发且未观察到术后并发症。与术前状态相比，患者的术后MSTS-93评分（（26.7 ± 2.4）vs.（18.8 ± 3.7），P < 0.05）和活动范围（（122.8° ± 9.1°）vs.（108.3° ± 6.1°），P < 0.05）显著改善。此外，软骨下骨厚度的均值增加到10.9 ± 1.3 mm（范围为9.1-12.1 mm）。三维打印纵梁型假体结合自体移植重建在远端股骨Ⅰ或Ⅱ级GCTB患者中具有可接受的早期功能和影像学结果，这是由于该假体具有良好的生物相容性、骨结合能力和软骨下骨保护等优点。如果我们的早期结果能够在更多患者和足够的随访研究中得到进一步验证，该方法可能被视为远端股骨Ⅰ或Ⅱ级GCTB的治疗选择之一。版权所有 © 2023 Tan, Li, Hu, Lu, Zhang, Gan, Tu and Min.

This study aimed to describe the design and surgical techniques of a three-dimensional (3D) printed strut-type prosthesis with a porous titanium surface for distal femur giant cell tumors of bone (GCTB) and evaluate the short-term clinical outcomes.From June 2018 to January 2021, 9 consecutive patients with grade I or II GCTB in the distal femur underwent extended intralesional curettage followed by 3D-printed strut-type prosthesis combined with autograft reconstruction were retrospectively reviewed to assess their clinical and radiographic outcomes.All patients were followed up for 30.8 ± 7.5 months (18-42 months) after surgery. The mean affected subchondral bone percentage and the mean subchondral bone thickness before surgery was 31.8% ± 9.6% (range, 18.2% ~50.2%) and 2.2 ± 0.8 mm (range, 1.2-4.0 mm), respectively. At the final follow-up, all the patients were alive without local recurrence; no postoperative complications were observed. Patients had significant improvements in postoperative MSTS-93 score [(26.7 ± 2.4) vs. (18.8 ± 3.7), P < 0.05], and ROM [(122.8° ± 9.1°) vs. (108.3° ± 6.1°), P < 0.05] compared with their preoperative statuses. Furthermore, the mean subchondral bone thickness has increased to 10.9 ± 1.3 mm (range, 9.1-12.1 mm).3D-printed strut-type prosthesis combined with autograft reconstruction provides acceptable early functional and radiographic outcomes in patients with grade I or II GCTB in distal femur due to the advantages of the prosthesis such as good biocompatibility, osseointegration capacity, and subchondral bone protection. If our early outcomes can be further validated in studies with more patients and sufficient follow-up, this method may be evaluated as an alternative for the treatment of grade I or II GCTB in the distal femur.Copyright © 2023 Tan, Li, Hu, Lu, Zhang, Gan, Tu and Min.